- Molecular NameRanolazine
- Synonym(-)-Ranolazine; ranolazine; Ranolazine 2HCl; Ranolazine Dihydrochloride
- Weight427.545
- Drugbank_IDDB00243
- ACS_NO142387-99-3
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)1.88
- pkaN/A
- LogD (pH=7, predicted)1.78
- Solubility (experiment)Slightly soluble
- LogS (predicted, ACD/Labs)(ph=7)-2.56
- LogSw (predicted, AB/LogsW2.0)45.75
- Sw (mg/ml) (predicted, ACD/Labs)0.99
- No.of HBond Donors2
- No.of HBond Acceptors7
- No.of Rotatable Bonds9
- TPSA74.27
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn antianginal medication.
- Absorption_valueN/A
- Absorption (description)Absorption is highly variable. After oral administration of ranolazine as a solution, 73% of the dose is systemically available as ranolazine or metabolites. The bioavailability of oral ranolazine relative to that from a solution is 76%.
- Caco_2N/A
- Bioavailability42.5
- Protein binding62.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic, metabolized mainly by CYP3A and to a lesser extent by CYP2D6. The pharmacologic activity of the metabolites has not been well characterized.
- Half life7 h
- ExcretionRenal (75%) and fecal (25%)
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityIn the event of overdose, the expected symptoms would be dizziness, nausea/vomiting, diplopia, paresthesia, and confusion. Syncope with prolonged loss of consciousness may develop.
- LD50 (rat)N/A
- LD50 (mouse)N/A